Some competition for 1592.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000600:supply & distribution / Q000627:therapeutic use*; D048588:Benzoxazines; D018791:CD4 Lymphocyte Count; D003521:Cyclopropanes; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage / Q000600:supply & distribution / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000600:supply & distribution / Q000627:therapeutic use*; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019469:Indinavir; D018119:Stavudine; C098320:efavirenz; D016049:Didanosine